

There was strong negative correlation between prolactin levels and length of treatment in a group of patients treated with risperidone ( $r=-0.42$ ) ( $p<0.05$ ). Prolactin level was decreasing with longer treatment.

#### Conclusions:

1. Hyperprolactinaemia occurs with nearly same prevalence in patients treated with risperidone and olanzapine.
2. Hyperprolactinemia affects more younger people treated with olanzapine.
3. Level of prolactin decreases with longer treatment with risperidone, but not with olanzapine.

### P150

Subjective attitude towards antipsychotics and neurocognitive functions in schizophrenic inpatients

B.H. Yoon<sup>1</sup>, A. Bae<sup>1</sup>, Y.H. Sea<sup>1</sup>, K.J. Kim<sup>1</sup>, S.H. Park<sup>1</sup>, W.M. Bahk<sup>2</sup>. <sup>1</sup> *Department of Psychiatry, Naju National Hospital, Naju, Jeonnam, South Korea* <sup>2</sup> *Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, South Korea*

**Objective:** This study aimed to examine the relationships between subjective attitudes towards antipsychotics and objective cognitive function in schizophrenia patients.

**Method:** The subjects of study were clinically stable schizophrenic patients (N=55) who were hospitalized in Naju National Hospital. They were grouped into positive (N=35) and negative drug attitude groups (N=20) by Drug Attitude Inventory (DAI-10). They were assessed using Positive and Negative Syndrome Scale, Calgary Depression Scale for Schizophrenia, Extrapyramidal Symptom Rating Scale, UKU side effect rating scale, Social and Occupational Functioning Assessment Scale and Subjective Well-being Under Neuroleptic Treatment. A battery of neurocognitive tests were also administered using Seoul Computerized Neurocognitive Function Test.

**Results:** Patients between positive and negative drug attitudes did not differ in social demographic and clinical characteristics. They also showed no differences in neurocognition tests except a subset of verbal auditory learning test.

**Conclusions:** These findings may indicate no associations between subjective drug attitudes and objective neurocognitive dysfunctions in schizophrenic inpatients. It suggests that subjective aspects measured by DAI may be a distinct dimension from objective neurocognitive profiles in terms of compliance.

### P151

Neuropsychological functioning in early-onset first-episode psychosis: lack of differences among diagnostic subgroups

A. Zabala<sup>1</sup>, I. Bombin<sup>1</sup>, M. Rapado<sup>2</sup>, P. Andres<sup>3</sup>, C. Gonzalez<sup>4</sup>, M. Mayoral<sup>1</sup>, O. Robles<sup>1</sup>, J.M. Rodriguez<sup>5</sup>, E. de la Serna<sup>6</sup>, C. Arango<sup>1</sup>. <sup>1</sup> *Unidad de Adolescentes. Dpto Psiquiatria, Hospital General Universitario Gregorio Marañón, Madrid, Spain* <sup>2</sup> *Dpto Psiquiatria, Clinica Universitaria de Navarra, Navarra, Spain* <sup>3</sup> *Dpto Psiquiatria, Hospital Infantil Universitario Niño Jesus, Madrid, Spain* <sup>4</sup> *Dpto Psiquiatria, Hospital Santiago Apóstol de Vitoria, Alava, Spain* <sup>5</sup> *Dpto Psiquiatria, Hospital Marques de Valdecilla, Cantabria, Spain* <sup>6</sup> *Dpto Psiquiatria, Hospital Clinic de Barcelona, Barcelona, Spain*

Cognitive impairment has been consistently described in adult-onset psychosis. A few studies have reported that cognitive impairment is present in early-onset schizophrenia. However, studies on other

psychoses are lacking and little is known about the potential specificity of cognitive impairment patterns among the differential sub-diagnoses.

**Aims:** 1) To examine the nature and extent of cognitive impairment in first-episode early-onset psychosis (EOP) and 2) To search for differential cognitive impairment profiles among the diagnosis subgroups.

**Methods:** This study describes the basal neuropsychological results of the child and adolescent first-episode psychosis study (CAFEPS), a Spanish multicenter longitudinal study. One hundred first-episode patients with EOP and 98 healthy controls underwent a comprehensive neuropsychological assessment. Three diagnostic categories were established: schizophrenia spectrum disorders (n=45), affective psychosis (n=28), and psychosis not otherwise specified (n=28). Baseline diagnoses were confirmed at a 6-month follow-up visit.

**Results:** Performance of patients was between 0.88 and 2 standard deviations below that of controls in all cognitive domains: attention ( $p<0.001$ ), working memory ( $p<0.001$ ), executive functioning ( $p<0.001$ ), and memory ( $p<0.001$ ). The three diagnostic subgroups did not differ from one another in terms of impaired/preserved cognitive functions and degree of impairment.

**Conclusions:** The pattern and degree of cognitive impairment in first-episode EOP patients is similar to that reported in first-episode adult-onset patients. Our results failed to identify significant differences among diagnostic subgroups at the onset of the illness. The longitudinal design of the present study will allow for identification of potential differences in the course of cognitive impairment.

### P152

Cognitive functioning in schizophrenic patients and their siblings

A.M. Zaharie<sup>1</sup>, I.V. Micluta<sup>2</sup>, C.A. Popescu<sup>1</sup>, M. Stanculete<sup>2</sup>. <sup>1</sup> *Psychiatric Hospital Nr. 2, Cluj-Napoca, Romania* <sup>2</sup> *University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania*

**Background:** Recent years have seen a particular attention towards the research of particularities of cognitive processes in schizophrenia.

**Objectives:** This study aims to investigate neuropsychological impairment in schizophrenia patients and their siblings.

**Method:** Cognitive functioning in 30 schizophrenia patients, 30 unaffected siblings and 30 unrelated healthy controls was assessed using verbal fluency tests (letters and categories) and several computerized memory and executive function tests.

**Results:** The patients performed significantly poorer than controls on all cognitive tests. Unaffected siblings demonstrated better performance than patients on some measures of spatial memory and executive function, but the performance was worse than controls. Patients and siblings demonstrated impaired verbal fluency performance.

**Conclusions:** Patients with schizophrenia and their unaffected siblings shared a deficit in verbal fluency.

## Poster Session 1: ANTIPSYCHOTIC MEDICATIONS

### P153

Use of antipsychotic drugs in Lithuanian clinical practice

V. Adomaitiene<sup>1</sup>, E. Kadusevicius<sup>2</sup>, L. Katajceva<sup>2</sup>. <sup>1</sup> *Department of Psychiatry, Kaunas Medical University and Hospital, Kaunas, Lithuania* <sup>2</sup> *Department of Basic and Clinical Pharmacology, Kaunas Medical University, Kaunas, Lithuania*

**Objective:** To evaluate trends in the use of antipsychotic drugs in Lithuania between 2003 and 2005 years.

**Methods:** The data on total sales of antipsychotic drugs in Lithuania over three years (2003–2005) were obtained from IMS Health Inc. Drugs were classified according to the Anatomic Therapeutic Chemical system, use was quantified in terms of defined daily doses. Data were calculated by DDD methodology, expressed in DDDs per 1,000 inhabitants/day. The pharmacoeconomic analysis was performed by cost minimization and reference price methodology.

**Results:** The total antipsychotics consumption increased by 16% over three years period reaching the value of 5,5 DDD/1000 inhabitants/day. Use of conventional antipsychotics has increased by 3%, atypical antipsychotics by 34%. The expenditures of antipsychotics has reached 39 mln Lit (in 2005), of which 48% was costs for atypical antipsychotic agents. Setting the reference price of risperidone (according to the meta-analysis results of effectiveness) for atypical antipsychotics it would be possible to rationalize schizophrenia treatment using 10,68 mln Lit extra money (1€ = 3,4528 Lt).

**Conclusions:** The use of total antipsychotic drugs continues to increase because of the increased use of atypical antipsychotics and some conventional antipsychotics. According to the meta-analysis results risperidone is the most effective drug for schizophrenia treatment. Considering the similar efficacy of other atypical antipsychotics and the increased high expenditures of atypical antipsychotics it is extremely important to consider the cost-effectiveness of antipsychotics. Performed cost-minimization analysis using the reference-based pricing estimated the possible reduction of total antipsychotics expenditures by 28%, the possible schizophrenia treatment rationalization.

## P154

Evaluation study on patient's attitude towards the psychiatric treatment

J.A. Aguado, O. Segurado, R.M. San Miguel. *Department of Psychiatry, Acute Unit, Benito Menni, Valladolid, Spain*

**Objective:** To evaluate attitude and adhesion of psychiatric patients towards its treatment, specially psychotic patients with neuroleptic treatment

**Material and method:** This is an open study on a population of 36 hospitalised patients in Acute Psychiatric Unit at Hospitality Center Benito Menni of Valladolid (Spain). Basic social-demographic information, characteristics of disease and treatment of each patient, their answers to an own questionnaire of quality assistance and scores derived from the application of Drug Attitude Inventory (DAI) has been collected in a protocolized form. These scores has been analysed with SSPS statistical program, crossing variables such as diagnosis or treatment.

**Results:** Some results are detailed as follows:

Male 38,9%, female 61,1%. Mean age 52,89. Usually single 50% that live alone 54,6% in urban habitat 65,6%, majority with schizophrenia 27,8%, followed by depressive spectrum 22,2%, with a combination of anxiolytics (lormetazepam + lorazepam) 33,3%, and risperidone (22,2%) or olanzapine (27,8%) in most cases.

After analysis we found statistical significance in differences by gender – better in case of women -, diagnosis – better attitudes with higher scores in patients with non psychotic disorder - and atypical neuroleptic treatment.

**Conclusions:**

1. Adherence and better attitudes were more likely in female patients, also schizophrenic, probably due to their caregivers role in society.

2. As expected, non psychotic patients with higher conscious of illness are more likely to see treatment as useful.
3. Atypical neuroleptics seems to be better in order to achieve proper treatment adherence

## P155

Being widowed - a high risk period for suicide

V. Ajdacic-Gross<sup>1</sup>, E. Gadola<sup>1</sup>, C. Lauber<sup>1</sup>, M. Bopp<sup>2</sup>, F. Gutzwiller<sup>2</sup>, W. Rossler<sup>1</sup>. <sup>1</sup> *Psychiatric University Hospital Zurich, Zurich, Switzerland* <sup>2</sup> *Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland*

**Objectives:** To address and better understand the problem of high suicide rates in widows and widowers.

**Methods:** Sex and age specific suicide data collated by marital group were extracted from Swiss mortality statistics for the period 1991–2003. The mortality in the first week / month / year of widowhood was calculated based on person-year calculations.

**Results:** Cross-sectional analysis by sex and age-group confirms the existence of different suicide rate patterns according to marital status. Moreover, the profiles of suicide methods differ. In particular, suicide methods which may be associated with impulsive suicides, such as firearms or poisoning, are relatively frequent in the widowed. The suicide risk of widowed persons is extremely high in the days and weeks immediately after bereavement.

**Conclusions:** Suicide risk and suicide behavior varies systematically according to marital status. In particular, widows and widowers emerge as a group suitable for preventive methods because of the existence of a time window when there is increased risk. Moreover, widowed persons are a clear-cut risk group under the aegis of undertakers, priests and perhaps general practitioners.

## P156

Prediction of antipsychotics gene targets by integration of genomic, evolutionary, and gene expression data

A. Ambesi-Impombato<sup>1,2</sup>, F. Panariello<sup>1</sup>, A. de Bartolomeis<sup>1</sup>, G. Muscettola<sup>1</sup>. <sup>1</sup> *Department of Neuroscience, University School of Medicine Federico II, Naples, Italy* <sup>2</sup> *Telethon Institute of Genetics and Medicine (Tigem), Naples, Italy*

**Background and aims:** Control of gene expression is essential for the establishment and maintenance of all cell types, and is involved in pathogenesis of several diseases. Accurate computational predictions of transcription factor regulation may thus help in understanding complex diseases, including mental disorders in which dysregulation of neural gene expression is thought to play a key role. However, predictions via bioinformatics tools are typically poorly specific.

**Methods:** We have developed and tested a computational workflow to computationally predict Transcription Factor Binding Sites on proximal promoters of vertebrate genes. The computational framework was applied to groups of genes found to respond to antipsychotic drugs. Our approach for the prediction of regulatory elements is based on a search for known regulatory motifs retrieved from TRANSFAC, on DNA sequences of genes' promoters. Predictions are thus weighted by conservation. These predictions are further refined using a logistic regression to integrate data from co-regulated genes.

**Results:** Consistent results were obtained on a large simulated dataset consisting of 5460 simulated promoter sequences, and on